MURA MURAL ONCOLOGY PUB LTD CO

Mural Oncology to Present at Two Upcoming Investor Conferences

Mural Oncology to Present at Two Upcoming Investor Conferences

WALTHAM, Mass. and DUBLIN, Aug. 27, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that members of its management team will participate at two upcoming investor conferences and take 1x1 meetings. A webcast of both presentations will be available at ir.muraloncology.com.

Morgan Stanley 22nd Annual Global Healthcare Conference

Fireside chat with Caroline Loew, Ph.D., CEO, Vicki Goodman, MD, Chief Medical Officer, and Adam Cutler, Chief Financial Officer

Date: Friday, September 6

Time: 1:50 p.m. ET

H.C. Wainwright 26th Annual Global Investment Conference

Presentation by Caroline Loew, Ph.D.

Date: Wednesday, September 11

Time: 9:30 a.m. ET

About Mural Oncology

Mural Oncology is leveraging its novel protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer. By combining our expertise in cytokine biology and immune cell modulation and our protein engineering platform, we are developing medicines to deliver meaningful and clinical benefits to people living with cancer. Our mission is to broaden the potential and reach of cytokine-based immunotherapies to improve the lives of patients. Our lead candidate, nemvaleukin, is currently in potentially registrational trials in mucosal melanoma and platinum-resistant ovarian cancer. Mural Oncology has its registered office in Dublin, Ireland, and its primary facilities in Waltham, Mass. For more information, visit Mural Oncology’s website at and follow us on and

Contact

Katie Sullivan



EN
27/08/2024

Underlying

MURAMURAL ONCOLOGY PUB LTD CO

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MURAL ONCOLOGY PUB LTD CO

 PRESS RELEASE
Free
MURA MURAL ONCOLOGY ...

Mural Oncology Announces Second Quarter Financial Results and Provides...

Mural Oncology Announces Second Quarter Financial Results and Provides Business Update Mural continues to explore strategic alternatives Estimates cash and cash equivalents of approximately $43 to $48 million at December 31, 2025, if it has not consummated a transaction or other strategic alternative by year end WALTHAM, Mass. and DUBLIN, Aug. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MURA), today announced its financial results for the second quarter of 2025 and provided a business update. On April 15, 2025, Mural announced that it was discontinuing all clinical development of its lead pr...

August 4, 2025 1 EN
 PRESS RELEASE
Free
MURA MURAL ONCOLOGY ...

Mural Oncology Announces Number of Relevant Securities in Issue

Mural Oncology Announces Number of Relevant Securities in Issue WALTHAM, Mass. and DUBLIN, May 19, 2025 (GLOBE NEWSWIRE) -- In accordance with Rule 2.12 of the Irish Takeover Panel Act 1997, the Irish Takeover Rules 2022 (the “Irish Takeover Rules”), Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company, (“Mural”) confirms that, as of the close of business on May 1, 2025, the issued share capital of Mural was 17,268,881 ordinary shares with par value US$0.01 each (the “Ordinary Shares”).   In addition, as of the close of business on March 31, 2025, there were outsta...

May 19, 2025 1 EN
 PRESS RELEASE
Free
MURA MURAL ONCOLOGY ...

FORM 8.1(a) & (b) - Mural Oncology plc

FORM 8.1(a) & (b) - Mural Oncology plc Ap9 FORM 8.1(a) & (b)(Opening Position Disclosure) IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE UNDER RULE 8.1(a) AND (b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR OR AN OFFEREE 1.      KEY INFORMATION (a)   Full name of discloser:Mural Oncology plc(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.N/A(c)   Na...

April 30, 2025 1 EN
 PRESS RELEASE
Free
MURA MURAL ONCOLOGY ...

Form 8.3 - The Vanguard Group, Inc.: Mural Oncology plc

The Vanguard Group, Inc. (IRSH) Form 8.3 - The Vanguard Group, Inc.: Mural Oncology plc 23-Apr-2025 / 14:38 GMT/BST Ap27   FORM 8.3   IRISH TAKEOVER PANEL   OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE   1. KEY INFORMATION             Full name of discloser The Vanguard Group, Inc.           Owner or controller of interests and short positions disclosed, if different from 1(a) The naming of nomin...

April 23, 2025 1 EN
 PRESS RELEASE
Free
MURA MURAL ONCOLOGY ...

Form 8.3 - The Vanguard Group, Inc.: Mural Oncology plc

The Vanguard Group, Inc. (IRSH) Form 8.3 - The Vanguard Group, Inc.: Mural Oncology plc 17-Apr-2025 / 14:20 GMT/BST Ap27   FORM 8.3   IRISH TAKEOVER PANEL   OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE   1. KEY INFORMATION             Full name of discloser The Vanguard Group, Inc.           Owner or controller of interests and short positions disclosed, if different from 1(a) The naming of nomin...

April 17, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch